Corbus Pharmaceuticals Holdings, Inc. Stock
Equities
CRBP
US21833P3010
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
39.24 USD | +7.42% | -3.94% | +549.67% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 384M |
---|---|---|---|---|---|
Net income 2024 * | -53M | Net income 2025 * | -65M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-7.02
x | P/E ratio 2025 * |
-7.13
x | Employees | 19 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.31% |
Latest transcript on Corbus Pharmaceuticals Holdings, Inc.
1 day | +7.42% | ||
1 week | -8.15% | ||
1 month | +0.18% | ||
3 months | +416.32% | ||
6 months | +554.00% | ||
Current year | +549.67% |
Managers | Title | Age | Since |
---|---|---|---|
Yuval Cohen
CEO | Chief Executive Officer | 49 | 13-06-30 |
Sean Moran
DFI | Director of Finance/CFO | 66 | 14-04-10 |
Chief Tech/Sci/R&D Officer | 50 | Feb. 27 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alan Holmer
CHM | Chairman | 74 | 13-12-31 |
Avery Catlin
BRD | Director/Board Member | 75 | 14-07-31 |
Yuval Cohen
CEO | Chief Executive Officer | 49 | 13-06-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 39.24 | +7.42% | 283,601 |
24-04-18 | 36.53 | -1.70% | 128,065 |
24-04-17 | 37.16 | -9.63% | 419,840 |
24-04-16 | 41.12 | -3.75% | 353,278 |
24-04-15 | 42.72 | +4.58% | 347,537 |
Delayed Quote Nasdaq, April 19, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+549.67% | 384M | |
-3.10% | 102B | |
+2.11% | 96.07B | |
-1.80% | 21.66B | |
-17.75% | 20.77B | |
-6.91% | 18.53B | |
-42.00% | 16.91B | |
-28.19% | 13.79B | |
+0.18% | 13.33B | |
+19.90% | 10.94B |
- Stock Market
- Equities
- CRBP Stock